All Stories

  1. Correspondence on “Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase”**

    Article • Angewandte Chemie, October 2022, Wiley

    Dr. Sandra W Cowan-Jacob

  2. The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug

    Article • Journal of Medicinal Chemistry, May 2022, American Chemical Society (ACS)

    Dr. Sandra W Cowan-Jacob

  3. Structural and Biochemical Studies Confirming the Mechanism of Action of Asciminib, an Agent Specifically Targeting the ABL Myristoyl Pocket (STAMP)

    Article • Blood, November 2020, American Society of Hematology

    Dr. Sandra W Cowan-Jacob

  4. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase

    Article • Leukemia Research, November 2020, Elsevier

    Dr. Sandra W Cowan-Jacob

  5. Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

    Article • British Journal of Cancer, June 2019, Springer Science + Business Media

    Dr. Sandra W Cowan-Jacob

  6. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

    Article • Journal of Medicinal Chemistry, August 2018, American Chemical Society (ACS)

    Dr. Sandra W Cowan-Jacob

  7. Imidazo[1,2- a ]pyridin-6-yl-benzamide analogs as potent RAF inhibitors

    Article • Bioorganic & Medicinal Chemistry Letters, December 2017, Elsevier

    Dr. Sandra W Cowan-Jacob

  8. The impact of structural biology in medicine illustrated with four case studies

    Article • Journal of Molecular Medicine, July 2017, Springer Science + Business Media

    Dr. Sandra W Cowan-Jacob

  9. The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

    Article • Nature, March 2017, Springer Science + Business Media

    Dr. Sandra W Cowan-Jacob

  10. Expanding the Opportunities for Modulating Kinase Targets with Allosteric Approaches

    Article • Current Topics in Medicinal Chemistry, November 2016, Bentham Science Publishers

    Dr. Sandra W Cowan-Jacob

  11. The role of structure and biophysics in the discovery of allosteric kinase inhibitors: ABL001, a potent and specific inhibitor of BCR-ABL

    Article • Acta Crystallographica Section A Foundations and Advances, August 2016, International Union of Crystallography

    Dr. Sandra W Cowan-Jacob

  12. Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors

    Article • Bioorganic & Medicinal Chemistry Letters, April 2016, Elsevier

    Dr. Sandra W Cowan-Jacob

  13. Type II Inhibitors Targeting CDK2

    Article • ACS Chemical Biology, July 2015, American Chemical Society (ACS)

    Dr. Sandra W Cowan-Jacob

  14. Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor

    Article • ACS Medicinal Chemistry Letters, May 2015, American Chemical Society (ACS)

    Dr. Sandra W Cowan-Jacob

  15. Ten things you should know about protein kinases: IUPHAR Review 14

    Article • British Journal of Pharmacology, March 2015, Wiley

    Dr. Sandra W Cowan-Jacob

  16. ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia

    Article • Blood, December 2014, American Society of Hematology

    Dr. Sandra W Cowan-Jacob

  17. Microseed matrix screening for optimization in protein crystallization: what have we learned?

    Article • Acta Crystallographica Section F Structural Biology Communications, August 2014, International Union of Crystallography

    Dr. Sandra W Cowan-Jacob

  18. Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases

    Article • Future Medicinal Chemistry, April 2014, Future Science

    Dr. Sandra W Cowan-Jacob

  19. Efficient Search of Chemical Space: Navigating from Fragments to Structurally Diverse Chemotypes

    Article • Journal of Medicinal Chemistry, October 2013, American Chemical Society (ACS)

    Dr. Sandra W Cowan-Jacob

  20. 2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes

    Article • Bioorganic & Medicinal Chemistry Letters, December 2011, Elsevier

    Dr. Sandra W Cowan-Jacob

  21. Fingolimod (FTY720) Inhibits BCR-ABL Signaling Allosterically by Binding to the Myristate Binding Site

    Article • Blood, November 2011, American Society of Hematology

    Dr. Sandra W Cowan-Jacob

  22. Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors

    Article • August 2011, Springer Science + Business Media

    Dr. Sandra W Cowan-Jacob

  23. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

    Article • Bioorganic & Medicinal Chemistry, October 2010, Elsevier

    Dr. Sandra W Cowan-Jacob

  24. Expanding the Diversity of Allosteric Bcr-Abl Inhibitors

    Article • Journal of Medicinal Chemistry, September 2010, American Chemical Society (ACS)

    Dr. Sandra W Cowan-Jacob

  25. New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck

    Article • Bioorganic & Medicinal Chemistry Letters, June 2010, Elsevier

    Dr. Sandra W Cowan-Jacob

  26. Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay

    Article • Journal of the American Chemical Society, May 2010, American Chemical Society (ACS)

    Dr. Sandra W Cowan-Jacob

  27. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site

    Article • Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, March 2010, Elsevier

    Dr. Sandra W Cowan-Jacob

  28. Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

    Article • Nature, January 2010, Springer Science + Business Media

    Dr. Sandra W Cowan-Jacob

  29. Discovery of 3-(1H-Indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a Potent and Selective Inhibitor of Protein Kinase C Isotypes

    Article • Journal of Medicinal Chemistry, September 2009, American Chemical Society (ACS)

    Dr. Sandra W Cowan-Jacob

  30. Structural biology contributions to tyrosine kinase drug discovery

    Article • Current Opinion in Cell Biology, April 2009, Elsevier

    Dr. Sandra W Cowan-Jacob

  31. Structural Biology Contributions to the Discovery of Drugs to Treat Chronic Myelogenous Leukemia

    Article • January 2009, Springer Science + Business Media

    Dr. Sandra W Cowan-Jacob

  32. Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib

    Article • Journal of Biological Chemistry, June 2008, Elsevier

    Dr. Sandra W Cowan-Jacob

  33. Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib

    Article • Biomolecular NMR Assignments, March 2008, Springer Science + Business Media

    Dr. Sandra W Cowan-Jacob

  34. Novel scaffold for cathepsin K inhibitors

    Article • Bioorganic & Medicinal Chemistry Letters, November 2007, Elsevier

    Dr. Sandra W Cowan-Jacob

  35. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

    Article • Blood, June 2007, American Society of Hematology

    Dr. Sandra W Cowan-Jacob

  36. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

    Article • Nature Reviews Drug Discovery, May 2007, Springer Science + Business Media

    Dr. Sandra W Cowan-Jacob

  37. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

    Article • Acta Crystallographica Section D Biological Crystallography, December 2006, International Union of Crystallography

    Dr. Sandra W Cowan-Jacob

  38. Structural biology of protein tyrosine kinases

    Article • Cellular and Molecular Life Sciences, October 2006, Springer Science + Business Media

    Dr. Sandra W Cowan-Jacob

  39. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

    Article • British Journal of Cancer, May 2006, Springer Science + Business Media

    Dr. Sandra W Cowan-Jacob

  40. Structural Biology of Protein Tyrosine Kinases

    Article • January 2006, Springer Science + Business Media

    Dr. Sandra W Cowan-Jacob

  41. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

    Article • Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, December 2005, Elsevier

    Dr. Sandra W Cowan-Jacob

  42. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

    Article • Cancer Research, June 2005, American Association for Cancer Research (AACR)

    Dr. Sandra W Cowan-Jacob

  43. The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation

    Article • Structure, June 2005, Elsevier

    Dr. Sandra W Cowan-Jacob

  44. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

    Article • Cancer Cell, April 2005, Elsevier

    Dr. Sandra W Cowan-Jacob

  45. Urea Derivatives of STI571 as Inhibitors of Bcr-Abl and PDGFR Kinases.

    Article • ChemInform, March 2005, Wiley

    Dr. Sandra W Cowan-Jacob

  46. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

    Article • Cancer Cell, February 2005, Elsevier

    Dr. Sandra W Cowan-Jacob

  47. Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases

    Article • Bioorganic & Medicinal Chemistry Letters, December 2004, Elsevier

    Dr. Sandra W Cowan-Jacob

  48. Novel Purine Nitrile Derived Inhibitors of the Cysteine Protease Cathepsin K

    Article • Journal of Medicinal Chemistry, October 2004, American Chemical Society (ACS)

    Dr. Sandra W Cowan-Jacob

  49. Structural studies of Imatinib in complex with its targets in CML and GIST: the molecular basis for selectivity and resistance

    Article • Acta Crystallographica Section A Foundations of Crystallography, August 2004, International Union of Crystallography

    Dr. Sandra W Cowan-Jacob

  50. Imatinib (STI571) Resistance in Chronic Myelogenous Leukemia: Molecular Basis of the Underlying Mechanisms and Potential Strategies for Treatment

    Article • Mini-Reviews in Medicinal Chemistry, March 2004, Bentham Science Publishers

    Dr. Sandra W Cowan-Jacob

  51. Structure of rabbit-muscle glyceraldehyde-3-phosphate dehydrogenase

    Article • Acta Crystallographica Section D Biological Crystallography, November 2003, International Union of Crystallography

    Dr. Sandra W Cowan-Jacob

  52. Imatinib: a selective tyrosine kinase inhibitor

    Article • European Journal of Cancer, September 2002, Elsevier

    Dr. Sandra W Cowan-Jacob

  53. STI571 (IMATINIB): structural and enzymatic studies of interactions with ABL kinase and resistance mutants

    Article • Acta Crystallographica Section A Foundations of Crystallography, August 2002, International Union of Crystallography

    Dr. Sandra W Cowan-Jacob

  54. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

    Article • Pharmacology & Therapeutics, February 2002, Elsevier

    Dr. Sandra W Cowan-Jacob

  55. Structural Basis of BFL-1 for Its Interaction with BAX and Its Anti-apoptotic Action in Mammalian and Yeast Cells

    Article • Journal of Biological Chemistry, April 2000, Elsevier

    Dr. Sandra W Cowan-Jacob

  56. Structures of adenylosuccinate synthetase from Triticum aestivum and Arabidopsis thaliana 1 1Edited by R. Huber

    Article • Journal of Molecular Biology, February 2000, Elsevier

    Dr. Sandra W Cowan-Jacob

  57. An Enzyme-Bound Bisubstrate Hybrid Inhibitor of Adenylosuccinate Synthetase

    Article • Angewandte Chemie, November 1999, Wiley

    Dr. Sandra W Cowan-Jacob

  58. Crystallization of a Polar Protein and Small Molecules from the Aqueous Compartment of Lipidic Cubic Phases

    Article • The Journal of Physical Chemistry, March 1997, American Chemical Society (ACS)

    Dr. Sandra W Cowan-Jacob

  59. Crystallization and preliminary crystallographic analysis of cabbage histidinol dehydrogenase

    Article • Acta Crystallographica Section D Biological Crystallography, November 1996, International Union of Crystallography

    Dr. Sandra W Cowan-Jacob

  60. The mode of action and the structure of a herbicide in complex with its target: binding of activated hydantocidin to the feedback regulation site of adenylosuccinate synthetase.

    Article • Proceedings of the National Academy of Sciences, September 1996, Proceedings of the National Academy of Sciences

    Dr. Sandra W Cowan-Jacob

  61. The structure of OmpF porin in a tetragonal crystal form

    Article • Structure, October 1995, Elsevier

    Dr. Sandra W Cowan-Jacob

  62. Electrostatic Properties of Two Porin Channels from Escherichia coli

    Article • Journal of Molecular Biology, July 1994, Elsevier

    Dr. Sandra W Cowan-Jacob

  63. Folding Pattern Diversity of Integral Membrane Proteins

    Article • Science, May 1994, American Association for the Advancement of Science

    Dr. Sandra W Cowan-Jacob

  64. Lipid-Binding Proteins: A Family of Fatty Acid and Retinoid Transport Proteins

    Article • January 1994, Elsevier

    Dr. Sandra W Cowan-Jacob

  65. Dialkylglycine Decarboxylase Structure: Bifunctional Active Site and Alkali Metal Sites

    Article • Science, August 1993, American Association for the Advancement of Science

    Dr. Sandra W Cowan-Jacob

  66. Prediction of membrane-spanning β-strands and its application to maltoporin

    Article • Protein Science, August 1993, Wiley

    Dr. Sandra W Cowan-Jacob

  67. Bacterial porins: lessons from three high-resolution structures

    Article • Current Opinion in Structural Biology, August 1993, Elsevier

    Dr. Sandra W Cowan-Jacob

  68. Structure Determination and Refinement of Human Alpha Class Glutathione Transferase A1-1, and a Comparison with the Mu and Pi Class Enzymes

    Article • Journal of Molecular Biology, July 1993, Elsevier

    Dr. Sandra W Cowan-Jacob

  69. Crystallographic Studies on a Family of Cellular Lipophilic Transport Proteins

    Article • Journal of Molecular Biology, April 1993, Elsevier

    Dr. Sandra W Cowan-Jacob

  70. Crystal structures explain functional properties of two E. coli porins

    Article • Nature, August 1992, Springer Science + Business Media

    Dr. Sandra W Cowan-Jacob

  71. Improved methods for building protein models in electron density maps and the location of errors in these models

    Article • Acta Crystallographica Section A Foundations of Crystallography, March 1991, International Union of Crystallography

    Dr. Sandra W Cowan-Jacob

  72. Crystallographic refinement of human serum retinol binding protein at 2Å resolution

    Article • Proteins Structure Function and Bioinformatics, January 1990, Wiley

    Dr. Sandra W Cowan-Jacob

  73. Crystallization of GST2, a human class alpha glutathione transferase

    Article • Journal of Molecular Biology, July 1989, Elsevier

    Dr. Sandra W Cowan-Jacob

  74. Binding of heparin to human platelet factor 4

    Article • Biochemical Journal, March 1986, Portland Press Ltd.

    Dr. Sandra W Cowan-Jacob

  75. Studies of Some Cadmium(II) and Mercury(II) Complexes With Dicyclohexylphosphino-N-Phenylthioformamide, LH: Crystal and Molecular-Structures of [Cdl2(LH)]2, ([HgCl2(LH)]2.CH2Cl2) And HgCl2(LH)2

    Article • Australian Journal of Chemistry, January 1986, CSIRO Publishing

    Dr. Sandra W Cowan-Jacob

  76. Crystallization and preliminary crystallographic data of the fab fragment of an anti-phenylalanine hydroxylase monoclonal antibody

    Article • Journal of Molecular Biology, November 1985, Elsevier

    Dr. Sandra W Cowan-Jacob

  77. A comparison of the molecular structures of Dicyclohexyl(N-phenylthiocarbamoyl)-phosphine and Diphenyl(N-phenylthiocarbamoy1)phosphine as determined by X-ray crystallography

    Article • Australian Journal of Chemistry, January 1984, CSIRO Publishing

    Dr. Sandra W Cowan-Jacob

  78. Crystal and molecular structure of orthorhombic dichloro-bis (o-ethylxanthato)tin(IV)

    Article • Inorganica Chimica Acta, January 1983, Elsevier

    Dr. Sandra W Cowan-Jacob

  79. Targeted Therapy with Imatinib: An Exception or a Rule?

    Article • Springer Science + Business Media

    Dr. Sandra W Cowan-Jacob